Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2.
Animal research · 2022
- What was studied
- Mouse models, cell assays including human osteoblasts, and observational human serum measurements
- Main finding
- The authors reported bone and inflammatory effects that disappeared after genetic or pharmacological disruption of CB2. Circulating OGP declined with age in the women sampled; this was not a treatment trial.
Study data at a glance
- Participants or experimental model
- Mouse models, cell assays including human osteoblasts, and observational human serum measurements
- Reported results
- The authors reported bone and inflammatory effects that disappeared after genetic or pharmacological disruption of CB2. Circulating OGP declined with age in the women sampled; this was not a treatment trial.
Study limitations and source details
Study limitations
- Mouse treatment and cultured human cells do not demonstrate human treatment efficacy.
- The human serum association cannot establish causation.
- Full-length OGP and the active fragment must be distinguished in each experimental method.
Source details
Journal article
Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Indexed abstract reviewed
Sources checked
Citation
B. Raphael-Mizrahi, M. Attar-Namdar, M. Chourasia, M. G. Cascio, Y. Gabet, et al.. Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2. eLife. 11:e65834
Study source ↗ · DOI 10.7554/eLife.65834 · Bibliography entry · Link to this summary